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CHAPTER 5
Adiponectin-Based  Therapeutics  for  Cancer
Treatment
Dahui Li, Handi Cao, Jie Chen, Ming Liu and Yu Wang*
State Key Laboratory of Pharmaceutical Biotechnology and Department of Pharmacology and
Pharmacy, The University of Hong Kong, Hong Kong, China
Abstract: Adiponectin is an adipokine predominantly produced from adipocytes and
exerts  potent  growth  inhibitory  activity  in  a  wide  range  of  cancer  cells.  Decreased
expression  and/or  function  of  adiponectin  are  associated  with  increased  risks  and
aggressive  development  of  cancers  with  poor  prognoses.  To  restore  the  expression
level  of  endogenous  adiponectin  and  to  activate  its  functional  pathways  represent
promising  strategies  for  the  prevention  and  treatment  of  cancer,  especially  in  obese
patients. However, the development of recombinant adiponectin as a therapeutic agent
has  been  hampered  by  the  complexity  of  its  structures  and  the  highly  diversified
functionality  of  this  magic  molecule.  Here,  the  application of  different  adiponectin-
based prophylactics and therapeutics in cancer treatment will be thoroughly reviewed
and scrutinized.
Keywords:  Adiponectin,  Adipokine,  Cancer,  Obesity,  Glycosylation,
Peptidomimetic,  Tumor  microenvironment,  Angiogenesis,  Therapeutics.
INTRODUCTION
Adiponectin (other names including adipocyte complement-related protein of 30
kDa (Acrp30) [1], AdipoQ [2], adipose most abundant gene transcript-1 (apM1)
[3],  and  gelatin-binding  protein  of  28  kDa  (GBP28)  [4])  is  a  soluble  matrix
protein  synthesized  predominantly  in  the  adipocytes  of  mammals  [5  -  7].  It
belongs to the expanding C1q/TNF-related protein (CTRP) family that contains
15  additional  paralogs,  designated  as  CTRP1–15  [8  -  10].  Most  adiponectin
paralogs  are  ubiquitously  expressed in  and secreted  from multiple  tissues  [11].
Homologues of mammalian adiponectin have been found in plants [12 - 14], and
bacteria  [15  -  19].  The  gene  of  human  adiponectin  (ADIPOQ)  is  located  on
chromosome  3q27  and  encodes  a  244-amino  acid  polypeptide  [20,  21].
Polymorphisms  of  ADIPOQ  affect  circulating  adiponectin  concentration  and/or
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function [22, 23], and modulates the metabolic phenotypes of obesity [24 - 26],
the susceptibility to type 2 diabetes [27 - 29], the risks of coronary and cerebral
artery diseases [30, 31], the severity of non-alcoholic fatty liver disease [32, 33],
as well as the aggressive development of various cancers [34 - 38].
Unlike  many  other  adipokines  released  from  adipose  tissue,  adiponectin  is
abundantly  present  in  the  circulation  and  acts  as  a  hormonal  factor  to  regulate
energy  metabolism,  immunity,  and  cellular  homeostasis  [39,  40].  In  animals,
replenishment  of  adiponectin  decreases  glucose production and restores  insulin
sensitivity [41 - 44], reduces visceral adiposity [45, 46], protects against hepatic
steatosis and inflammatory liver diseases [47 - 51], attenuates the development of
atherosclerotic vascular disease [52 - 56], and inhibits cancer development [57 -
62]. The diversified biological functions and therapeutic potentials of adiponectin
have  been  thoroughly  summarized  by  many  excellent  reviews  [63  -  72].  The
present chapter mainly focuses on the approaches, challenges and controversies as
well as the future aspects in the development of adiponectin-based therapeutics
for cancer diseases.
STUCTURAL POLYMORPHISM OF OLIGOMERIC ADIPONECTIN
The primary structure of adiponectin contains an NH2-terminal signal peptide and
a  species-specific  variable  region,  followed  by  a  collagen-like  domain  with  22
Gly-X-Pro or Gly-X-Y repeats and a COOH-terminal globular domain (Fig. 1);
the  latter  exhibits  similar  three-dimensional  folding  topology  with  the  pro-
inflammatory  cytokine,  tumor  necrosis  factor  alpha  (TNF-α)  [73,  74].  In
adipocytes,  adiponectin  is  synthesized  as  a  monomeric  subunit  that  undergoes
oligomeric  assembly  to  form  trimers,  hexamers,  and  high  molecular  weight
(HMW) multimers (Fig. 1) [75]. Trimerization of adiponectin is triggered by the
hydrophobic interactions between the globular domains [74, 76, 77]. Two trimers
are cross-linked to form hexamers via the disulfide bridges between the cysteine
39 residue of the variable region [78 - 80].  A number of chaperones,  including
endoplasmic  reticulum  protein  44  (ERp44),  ER  oxidoreductase  1-like  protein
alpha  (Ero1-Lα)  and  disulfide-bond-A  oxidoreductase-like  protein  (DsbA-L),
interact  with  the  variable  region  of  adiponectin  and  facilitate  the  reduction  of
oxidized trimers and hexamers, thus assuring an efficient assembly and release of
HMW oligomers [81 -  86].  Multiple  trimers assemble to form the higher  order
structures of HMW adiponectin, resembling a “bouquet” of collagenous stalk and
“blossoms” of the globular heads [87]. Hydroxylation and glycosylation of several
conserved lysine residues within the collagen-like domain are indispensable for
the formation of HMW adiponectin complexes (Fig. 1) [6, 78 - 80, 88 - 90].
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Fig. (1).  Schematic illustrations of the primary structure (upper panel) and the oligomeric complex assembly
(lower panel) of human adiponectin.
From the NH2- to COOH-terminus, the primary sequence of adiponectin consists
of  a  signal  peptide,  a  variable  region,  a  collagen-like  domain  and  a  globular
domain.  Adiponectin  is  extensively  modified  during  the  process  of  oligomeric
assembly:  The  cysteine  (C)  36  residue  forms  intra-  and  inter-trimer  disulfide
bridges,  depicted  as  “S-S”  [76];  The  tryptophan  (W)  39  residue  modulates  the
interactions with ERp44 and the oxidative folding of trimers and hexamers [85];
A number of proline (P) and lysine (K) residues located within the collagen-like
domain  are  post-translationally  modified  by  hydroxylation  [88  -  90];
Glycosylation of the hydroxylated lysines plays a crucial role in the formation of
adiponectin HMW oligomers [6, 89]; A number of endoplasmic reticulum (ER)
chaperones  are  responsible  for  the  reduction  of  fully  oxidized  trimers  and
hexamers  for  HMW  assembly  [86].
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Once  released  into  the  blood,  the  trimers,  hexamers  and  HMW  adiponectin
oligomers  do  not  spontaneously  interconvert  and  exhibit  non-overlapping
biological activities by targeting distinct receptors and signaling pathways [73, 76,
78, 80, 91 - 97]. The circulating level of HMW adiponectin is considered the most
relevant biomarker for disease-associated adipocyte dysfunctions [63, 98 - 101].
High levels of HMW adiponectin are associated with favorable metabolic profile
[92, 102, 103]. The circulating concentration of adiponectin ranges from ~10 to
30  μg/ml,  approximately  1000-fold  higher  than  other  hormonal  factors  and
accounting for ~0.1% of total protein in human plasma [5, 102, 104, 105]. Under
obesity and associated pathological conditions, the plasma levels of adiponectin
are significantly decreased – a phenomenon referred to as hypoadiponectinaemia,
which is caused by the reduced gene expression and/or protein assembly/secretion
of this molecule in adipocytes [2, 104, 106 - 111]. Thus, the protective effects of
adiponectin  on  the  pathogenesis  of  insulin  resistance,  atherosclerosis,
inflammation and cancers are significantly compromised by weight gain [112]. In
animals,  replenishment  of  adiponectin  leads  to  remarkable  remedial  activities
against  various  obesity-related  medical  complications  [44,  113].  However,  the
structural polymorphism and the high abundancy of this molecule in circulation
have  posted  major  challenges  to  produce  large  amounts  of  homogenous  and
bioactive  adiponectin  for  therapeutic  applications  in  human.
RECEPTORS AND SIGNALING PATHWAYS OF ADIPONECTIN
Adiponectin receptors  1 (AdipoR1) and 2 (AdipoR2) are  seven transmembrane
domain receptors originally identified by molecular cloning strategies using the
globular  domain  of  adiponectin  as  a  bait  probe  [114,  115].  Consequently,  both
receptors  show  relatively  higher  affinities  to  the  COOH-terminal  globular
fragment than the full-length molecule of adiponectin [63, 94]. The two receptors
share 67% identity in protein sequences and show an atypical topology different
from the conventional G-protein-coupled receptor, with an internal NH2-terminus
and  external  COOH-terminus  [63,  94].  Adiponectin  stimulates  the
phosphorylation  of  AMP-activated  protein  kinase  (AMPK)  through  AdipoR1,
whereas its effects on peroxisome proliferator-activated receptor alpha (PPARα)
are mediated by AdipoR2 [114, 116].
AdipoR1 and AdipoR2 are widely expressed in many organs/tissues but differ in
the  pattern  of  distribution and the  relative  abundance [114,  117].  For  example,
AdipoR1  is  relatively  more  abundant  in  skeletal  muscle  whereas  AdipoR2  is
predominantly  expressed  in  liver  [117].  Moreover,  the  expression  levels  of
AdipoR1  and  AdipoR2  are  affected  by  status  of  adiposity  and  diabetes  [118],
plasma  insulin  and  adiponectin  levels  [118,  119],  food  intake  (increase  with
fasting and decrease with feeding) [120, 121], physical activity [120, 122, 123],
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and age [124]. Human and murine AdipoR share over 95% sequence homology
[114,  116].  Genetic  polymorphisms of  human ADIPOR1  and ADIPOR2  do  not
display a significant correlation with the development of obesity-related metabolic
abnormalities [125 - 133].
Disruption of AdipoR1 and/or AdipoR2 partially abolishes the metabolic actions
of  adiponectin,  leading  to  the  development  of  insulin  resistance  especially  in
skeletal  muscle  and  adipose  tissues  [118,  134].  However,  the  phenotypes  of
adiponectin-deficient  mice  have  not  been  thoroughly  replicated  by  the
AdipoR1/R2  dual-deficient  mice  [116].  Moreover,  a  number  of  studies  have
suggested  a  pro-inflammatory  role  of  AdipoR1/R2  [135,  136].  AdipoR1  and
AdipoR2,  as  well  as  other  members  of  the  progestin  and  AdipoQ  receptor
superfamily,  possess  potent  ceramidase  activities  to  produce  ceramide  and
phosphorylated sphingoid, which are causatively involved in the development of
insulin resistance, atherosclerosis and heart failure [137 - 140]. In this regard, a
key question to be answered is whether or not by binding to AdipoR, adiponectin
acts to inhibit their activities and if so, which oligomeric form(s) of adiponectin
function as the antagonists.
T-cadherin (also known as CDH13, cadherin 13, and H-cadherin) is a “truncated”
cadherin  anchored  on  the  plasma  membrane  of  cells  via  a
glycosylphosphatidylinositol linkage [141, 142]. It acts as an adiponectin receptor
and binds to the hexamers and HMW multimers [143]. Due to the lacking of the
transmembrane  and  intracellular  domains,  T-cadherin  is  considered  to  have  no
direct effects on adiponectin-mediated signal transduction in cells, but regulates
the circulating levels and tissue distribution of this adipokine [144, 145]. Genetic
studies  have  shown  that  single  nucleotide  polymorphisms  in  CDH13,  the  gene
encoding human T-cadherin, contribute to low levels of adiponectin [146 - 151].
In T-cadherin-deficient mice, adiponectin accumulates in the circulation at higher
than normal levels [145, 147 - 149, 152]. Meanwhile, a significant reduction in
the tissue content of adiponectin leads to an increased susceptibility of these mice
to  injuries  caused  by  inflammatory  stimuli  [145,  153].  Notably,  T-cadherin  is
abundantly  expressed  in  injured  vascular  endothelial  and  smooth  muscle  cells,
such  as  those  of  the  atherosclerotic  plaques  [141,  154,  155].  Without  this
molecule, heart and vascular tissues become insensitive to adiponectin, despite a
constant  expression  of  AdipoR1/R2  in  T-cadherin-deficient  mice  [141].
Consistently, the vascular dysfunction and ischemia-induced heart problems have
been observed in T-cadherin-deficient mice, similar to those of the adiponectin-
deficient mice [154, 156, 157]. In human, genetic polymorphisms of CDH13 are
significantly  associated  with  various  cardiometabolic  and  vascular  phenotypes
[144, 146, 151, 154, 158, 159].
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In  summary,  the  evidence  supports  a  synergistic  role  of  T-cadeherin  in
adiponectin-mediated  beneficial  functions.  However,  without  elucidating  the
detailed structural mechanisms underlying the interactions between adiponectin
and  T-cadeherin,  further  development  of  therapeutics  based  on  this  “third
promising  receptor”  remain  elusive.
ADIPONECTIN  AND  ITS  RECEPTORS  IN  OBESITY-RELATED
CANCER DISEASES
Excess adiposity is an independent risk factor for the development of cancer and
closely associated with late-stage disease and poor prognosis [160 - 163]. Adipose
tissue  is  the  largest  endocrine  organ  in  human  body  [164].  During  obesity,
excessive expansion of the fat depots leads to chronic adipose tissue inflammation
and the augmented productions of inflammatory adipokines, which act directly on
tumor cells to promote their survival and proliferation [91, 165 - 169]. In addition,
dysregulated  metabolic  homeostasis,  characterized  by  hyperinsulinemia,
hyperglycemia  and  dyslipidemia,  indirectly  enhances  tumor  growth  and
development  in  obese  patients  [170  -  172].  Increasing  insulin  and  insulin-like
growth factors (IGF) contribute to carcinogenesis [173, 174]. Moreover, adipose
tissue located in proximity to or within the tumor microenvironment contributes to
the local production of carcinogenic matrix proteins and the continuous supply of
cancer stem cells [175, 176].
In  obese  subjects,  hypoadiponectinaemia  (<4  μg/ml)  is  associated  with  an
increased  risk  of  developing  cancers  including  but  not  limited  to  those  of  the
breast  [177,  178],  endometrium [179 -  182],  prostate  [183],  colon  [184 -  186],
stomach  [187  -  189],  pancreas  [190],  liver  [191,  192],  kidney  [193  -  195],
leukemia  [196,  197],  lymphoma  and  myeloma  [198  -  201].  Moreover,  tumors
from  patients  with  low  plasma  adiponectin  levels  are  larger,  exhibiting  higher
histologic  grade,  more  aggressive  invasion  and  metastasis,  as  well  as  poorer
prognosis [182, 183, 189, 202 - 211]. High plasma adiponectin levels, especially
those of the HMW oligomers, are associated with a decreased cancer risk [180,
203, 212 - 216].  Genetic polymorphisms of the ADN  gene affect its  circulating
levels, the tumor grade, clinical stage and aggressiveness in cancer patients [36,
126, 217 - 221]. Taken in conjunction, hypoadiponectinaemia not only represents
a  useful  biomarker  for  early  detection  but  also  plays  a  causative  role  in  the
development  of  obesity-related  cancer  diseases.
The adiponectin receptors AdipoR1 and AdipoR2 are expressed in a plethora of
malignant tissues including breast,  endometrium, prostate,  esophagus,  stomach,
colon,  liver,  pancreas,  and lung [222 -  230].  Contrary to adiponectin,  AdipoR1
and AdipoR2 exhibit an inconsistent pattern of change in both the expression and
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distribution  across  different  types  of  tumors  and  relative  to  the  normal/benign
tissues. For instance, the expression of AdipoR1 and AdipoR2 is downregulated
in  cancerous  in  comparison  to  healthy  prostate  tissues  [220],  but  increased  in
tumor tissues of both non-small and small cell lung cancer [222 - 230]. In gastric
cancer, the expression levels of AdipoR1 and AdipoR2 are lower in tumor than
normal  tissue  and  acts  as  a  marker  of  better  prognosis  [231].  However,  higher
expression  of  AdipoR2  is  associated  with  moderately  differentiated  when
compared to well-differentiated gastric tumors [232]. Pancreatic cancer patients
show  positive  or  strong  expression  of  AdipoR1/R2  in  the  tumor  tissues  [228].
Significantly  increased  or  decreased  expressions  of  AdipoR1 and  AdipoR2 are
found in colorectal cancer tissues versus normal colon epithelium [233 - 237]. A
higher  expression  of  AdipoR1 is  found  in  tumor  tissue  and  cell  lines  of  breast
cancer [225, 238, 239], and associated with a more invasive phenotype [239, 240].
In  addition  to  the  highly  variable  expression  patterns  of  AdipoR1/R2  in  tumor
tissues, studies of their genetic polymorphisms in different populations of cancer
patients  preclude  the  application  of  these  receptors  as  either  biomarkers  or
suitable  targets  for  therapeutic  development  in  cancer  diseases  [126,  127,  231,
241 - 246].
ANTI-TUMORIGENIC ACTIVITY OF ADIPONECTIN
Unlike most of the inflammatory adipokines that are causally linked to obesity-
related  diseases,  adiponectin  possesses  potent  insulin-sensitizing,  anti-
inflammatory, anti-angiogenic and anti-tumorigenic activities [6, 47, 62, 63, 247 -
249].  Adiponectin  prevents  cancer  development  by  improving  the  energy
metabolism systemically and suppressing the actions of pro-inflammatory or pro-
tumorigenic  modulators  in  the  tumor  microenvironment  locally  [250  -  253].  It
selectively  binds  to  various  carcinogenic  growth  factors  to  prevent  their
interactions  with  the  respective  receptors  [247,  254].  Most  importantly,
adiponectin released from adipocytes acts as an endocrine and a paracrine factor
to  directly  inhibit  the  survival,  growth  and  invasion  of  cells  in  the  tumor
microenvironment, via both receptor-dependent and independent mechanisms [59,
191, 216, 248].
Inhibition of Tumor Cell Growth by Adiponectin
Adiponectin  elicits  potent  cytostatic  actions  to  suppress  the  proliferation  of
various  types  of  cells,  including  endothelial  and  smooth  muscle  cells,
myelomonocytic cells, hepatic stellate cells, satellite cell,  myoblast and various
different  types  of  cancer  or  stem  cells  [57,  59,  247,  254  -  261].  Adiponectin
inhibits the in vitro growth of human breast cancer MDA-MB-231, T47D MCF7
and SK-BR-3 cells, as well as the non-cancerous MCF10A and human mammary
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epithelial cells [61, 238, 262 - 274]. Animal studies demonstrate that supplement
therapy with mammalian adiponectin suppresses the tumor development in mice
implanted with human breast cancer cells [61, 238, 275].
Adiponectin, in particular the HMW form at a sub-physiological concentration,
inhibits leptin-, IGF-1- or dihydrotestosterone-stimulated proliferation of prostate
cancer  cells  [276,  277].  It  enhances  the  inhibitory  effects  of  doxorubicin,  a
cytotoxic  chemotherapy  agent,  on  prostate  cancer  cell  growth  [276,  277].
Treatment  with  adiponectin  reduces  the  viability  and  inhibits  growth  factor-
induced  proliferation  and  invasion  of  endometrial  cancer  cells  [224,  276,  278,
279],  hepatic  carcinoma  cells  [280,  281],  colorectal  cancer  cells  [282],  gastric
cancer cells [189], esophageal cancer cells [283], pancreatic cancer cells [284],
and lung cancer cells [227]. Prolonged exposure to adiponectin induces cell cycle
arrest and apoptosis in multiple types of myeloma cells [285, 286]. It enhances the
sensitivity of  human chronic myelogenous leukemia cells  to imatinib treatment
[207, 287 - 290].
Depending on the experimental model, cytostatic/apoptotic effects of adiponectin
are mediated by the increased activation of AMPK [230, 291, 292], the reduced
signal transduction through extracellular-signal-regulated kinases 1 and 2, p38 or
c-Jun N-terminal kinases [117, 270, 293], the inhibition of Wnt signaling or Akt
and glycogen synthase kinase 3β/β-catenin pathways [61, 294, 295],  and/or the
enhanced  expression  of  Bax,  p53  and  p21,  which  are  important  regulators  of
growth  arrest  and  apoptosis  [230,  274,  296,  297].
Inhibition of Tumor Angiogenesis by Adiponectin
In  vascular  endothelial  cells,  the  cross-talks  between  adiponectin-mediated
activation of AMPK (a cytostatic factor to inhibit both growth and death [298 -
301])  and  inhibition  of  Akt/protein  kinase  B  (a  signal  to  promote  survival  and
growth [302])  determine the outcome of vascularization or angiogenesis  [303 -
306].  By  activating  endothelial  nitric  oxide  synthase  via  AMPK,  adiponectin
elicits  potent  anti-apoptotic  and  anti-oxidant  activities  during  ischemia-
reperfusion injury, thus facilitating revascularization [6, 252, 255, 305, 307, 308].
In the setting of  tumor development,  a  condition that  differs  significantly  from
tissue ischemia [309 - 311], adiponectin inhibits the activation, proliferation and
migration of vascular endothelial cells, and prevents new blood vessel formation
[57, 153, 252, 255, 305, 307, 308, 312 - 315]. By contrast, the globular domain of
adiponectin  increases  endothelial  activation,  proliferation,  migration  and
angiogenesis, largely through its binding to AdipoR1 or AdipoR2 [306, 307, 316 -
322].  In  human  vascular  endothelial  cells,  globular  adiponectin  stimulates  the
formation of capillary-like structures and acts as a chemoattractant [306]. It also
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restores the function of endothelial progenitor cells under high glucose conditions
[318].  While  the  evidence  support  certain  pharmacological  properties  of  the
globular domain, the existence and presence of this adiponectin fragment in vivo
has not been confirmed under both physiological and pathological conditions [1,
3, 4, 321, 323, 324].
T-cadherin plays a role in the crosstalks between adiponectin and vasculogenic
factors as well as AdipoR in the tumor microenvironment [311, 325 - 327], and
enhances  endothelial  barrier  function  [328].  It  may  act  as  a  co-receptor  by
competing  with  AdipoR1  and  AdipoR2  receptors  for  adiponectin  binding  or
interfering with adiponectin signal transduction [329]. Nevertheless, the role of T-
cadherin in tumor angiogenesis remain to be elucidated.
ADIPONECTIN-DERIVED ANTI-CANCER THERAPEUTICS
Despite  that  adiponectin  elicits  potent  activities  against  obesity-related
pathologies  [43,  44,  330],  it  is  extremely challenging to convert  the full-length
molecule  into  a  peptidomimetic  drug for  the  therapeutic  applications  in  human
[331, 332]. Therefore, efforts have been directed towards the identification and
testing of the active moieties on adiponectin. Based on earlier studies [52, 333 -
335],  Otvos  et  al.  designed  a  series  of  overlapping  peptides  across  the  entire
globular  domain  of  adiponectin  and  tested  their  agonistic  effects  on  AdipoRs
[336].  A  lead  peptidomimetic,  ADP355  (H-DAsn-Ile-Pro-Nva-Leu-T-
r-DSer-Phe-Ala-DSer-NH2) with four non-natural amino acid replacements, was
generated  to  elicit  cytostatic  and  anti-oncogenic  activities  primarily  through
AdipoR1 [337]. Subsequently, a number of derivatives of ADP355 were designed
for testing the anti-proliferative activities in MCF-7 breast cancer cells and K562
chronic  myeloid  leukemia  cells  [331,  338].  A  bell-shaped  dose-response  curve
was  observed  for  all  the  ADP  adiponectin  peptidomimetics,  i.e.  the  growth
inhibition  reversed  at  high  dose  [338].  The  variable  activities  of  the  ADP
peptidomimetics are probably due to cell type-specific mechanisms and involve
additional  signaling  biopolymers  apart  from  AdipoRs  [331].  Although
multimerization of the peptide ligands enhances the cellular activities, none of the
ADP peptidomimetics exerts favorable effects on the inhibition of endothelial cell
mitogenesis [339].
While the pharmacological properties of the ADP355 derivatives are worthwhile
further exploration, the rationale for their applications in cancer treatment needs
to  be  thoroughly  re-reviewed.  First  of  all,  although  there  is  evidence  that
activation of AdipoR receptors limits the proliferation of cancer cell lines in vitro
[222, 230, 238], studies have not been able to demonstrate any robust inhibitory
effects of the globular domain on the proliferation of breast, colorectal, prostate
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and leukemia cancer cells [238, 263, 264, 269, 270, 274, 277, 340 - 342]. On the
other hand, the globular form of adiponectin has been reported to be associated
with the development of colorectal and breast cancer [324, 343]. Second, most of
studies  have  utilized  bacterially-produced  recombinant  protein  representing  the
globular domain, which is not detected under pathophysiological conditions; thus
its  roles  in  cancer  development  are  insufficiently  connected  to  the  in  vivo
functions of the properly glycosylated adiponectin [323, 333]. Third, the structural
similarity  between  the  globular  domain  and  TNF-α  may  not  necessarily  be
translated into the anti-tumor but rather the pro-tumor and inflammatory activities,
partly through the stimulation of  AdipoR1/R2 [139,  173,  324,  329,  344 -  346].
The latter is associated with an increased ceramidase activity and production of
the anti-apoptotic metabolites, sphingolipid ceramide [139, 347].
A recent study attempted to identify non-peptidic AdipoR agonists from a natural
product library, using ADP355 as a reference compound [348]. The most active
agonists  are  matairesinol,  arctiin,  (-)-arctigenin  and  gramine  for  AdipoR1,
parthenolide, taxifoliol, deoxyschizandrin and syringing for AdipoR2. Most of the
hit compounds possess potent anti-oxidative and anti-proliferative properties [112,
349]. However, as the involvement and role of AdipoR in cancer cell proliferation
and tumor growth remain to be established [139, 350], results derived from the
receptor-based  screening  experiment  need  to  be  carefully  scrutinized  to
differentiate  the  agonistic  or  antagonistic  effects  [348].  AdipoR1 and AdipoR2
form homo- and hetero-multimers, which influence the ligand binding and thus
drug  compound  screening  [63,  91,  351].  Multimerization  by  binding  with
different  ligands  may  activate  distinct  signaling  pathways,  via  modulating  the
alternative  interactions  with  the  intracellular  adaptor  protein,  APPL1  (adaptor
protein, phosphotyrosine interacting with PH domain and leucine zipper 1) [352 -
354]. The latter mediates the signaling of AdipoR to promote the proliferation and
migration of cancer cells [329, 355].
Okada-Iwabu  et  al.  screened  a  compound  library  and  identified  several  small-
molecule AdipoR agonists [356]. One of them, AdipoRon, binds to AdipoR1 and
AdipoR2 at low micromolar concentrations and activates AMPK as well as the
transcriptional  coactivator,  peroxisome  proliferator–activated  receptor  gamma
(PPARγ) coactivator 1–alpha [115, 357]. Like adiponectin, AdipoRon improves
energy  metabolism and  insulin  sensitivity,  in  turn  extending  life  span  in  obese
animals  [357].  Meanwhile,  AdipoR-  or  adiponectin-independent  effects  of
AdipoRon have been identified and reported [357 - 363]. Nevertheless, the effects
of the low molecular weight agonists of AdipoR on tumor development remain to
be explored.
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ALTERNATIVE  STRATEGIES  FOR  ADIPONECTIN  REPLACEMENT
THERAPIES
Despite  the  existing  controversies  on  AdipoR  and  their  agonists,  there  are
compelling  evidence  supporting  a  key  role  of  hypoadiponectinaemia  in  the
pathogenesis of malignant diseases associated with obesity [216, 279, 349, 364].
Increasing circulating adiponectin levels counteracts metabolic dysfunction and
slows  cancer  progression  in  experimental  models  [286,  365].  Given  that  it  is
difficult to convert the full-length adiponectin protein into a viable drug, restoring
the  balanced  production  and  mimicking  the  cancer-protective  effects  of
adiponectin have attracted significant interests for potential clinical applications.
For example, metformin, a biguanide derivative and first-line oral medication for
type  2  diabetes  mellitus,  stimulates  AMPK  to  inhibit  a  number  of
anabolic/mitogenic  pathways  activated  by  growth  factors  and  nutrients,  thus
eliciting  similar  anti-tumorigenic  effects  as  adiponectin  [366  -  379].
Circulating adiponectin levels are modulated by lifestyle, dietary components and
pharmacological agents [380 - 386]. Body weight loss, particularly in the form of
visceral fat reduction, is effective in boosting the plasma adiponectin levels [387,
388].  Calorie  restriction  induces  AMPK  signaling  in  tumor  tissues  and  exerts
anticancer  effects,  concurrent  with  an  augmented  adiponectin  levels  [389].
Specific dietary components for cancer prevention, such as omega-3 and vitamin
D, increase adiponectin expression and secretion [390 - 392]. Astragaloside II and
isoastragaloside  I,  the  active  ingredients  of  anticancer  medicinal  herb  Radix
Astragali, increase adiponectin production from adipocytes [393]. The molecular
mechanisms  underlying  the  modulation  of  adiponectin  levels  by  body  weight
reduction or dietary components remain unclear. Nevertheless, it is suggested that
obesity-induced endoplasmic reticulum stress leads to a decreased production of
adiponectin, especially the HMW form [394, 395]. Thus, targeting the machinery
responsible  for  adiponectin  assembly  and  secretion  represents  an  attractive
strategy  for  elevating  the  circulating  levels  of  this  molecule  [396].
Adiponectin is secreted from adipocytes into the bloodstream as three oligomeric
isoforms.  Both  clinical  and  animal  studies  suggest  that  the  HMW  is  the
predominant  isoform  mediating  the  beneficial  effects  of  adiponectin  [79,  397,
398].  L-4F,  an  apolipoprotein  A-I  mimetic  peptide,  increases  serum
concentrations  of  HMW  adiponectin  in  obese  mice  [399],  and  reduces  tumor
burden through induction of myeloma cell apoptosis [400]. Administration of the
PPARγ agonist thiazolidinediones (TZDs, a class of drugs used to improve lipid
and glucose  metabolism in  type  2  diabetes  [401])  in  both  diabetic  patients  and
rodents results in a selective elevation in serum levels of the HMW oligomer via
stimulating  the  biosynthesis  and  secretion  pathways  of  adiponectin  [109,  391,
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402, 403]. In vitro and in vivo treatment with TZDs inhibits the growth, migration
and  invasion  of  cancer  cells  [403  -  408].  Leuprolide,  a  gonadotropin-releasing
hormone  agonist,  increases  plasma  adiponectin  levels  in  nondiabetic  men  with
prostate  cancer  when  combined  with  androgen  blockade,  bicalutamide  [409].
While the above evidence suggest that pharmacological intervention is feasible to
modulate circulating adiponectin levels, a specific target to effectively sustain the
expression and/or production of adiponectin remain to be identified.
Adiponectin shares homology with collagen VIII and X, complement factor C1q
and  TNF-α  [73,  261].  Adiponectin  may  act  as  soluble  defense  collagen  by
negatively regulating the functions of inflammatory cells [261]. Apart from the
globular domain, there are other pharmacological moieties of adiponectin remain
to  be  explored  and  examined.  For  example,  a  number  of  groups  have  adopted
chemical  synthetic  approaches  to  produce  non-globular  adiponectin  fragments.
Among them, the adiponectin variable domain [410], and the post-translationally
modified collagen-like domain [411], might prove beneficial for the treatment of
obesity-related  malignant  diseases.  A  full  uncover  of  the  structure/function
relationships of different domains of adiponectin will facilitate the conversion of
this magic molecule into a viable drug.
CONCLUDING REMARKS
Obesity  is  a  global  epidemic  problem  with  widespread  health  consequences,
including  an  increase  in  the  incidence  and  death  of  many  lifestyle-related
malignant  diseases.  The  need  for  cancer  prevention  and  therapies  is  of  upmost
importance. Adiponectin represents a critical link between obesity and many types
of  cancer  development.  Epidemiological,  genetic,  and  animal  studies  have
demonstrated  the  protective  effects  of  adiponectin  against  a  cluster  of  obesity-
related metabolic, cardiovascular and malignant complications. Various strategies
to  increase  the  circulating  level  and  function  of  adiponectin  have  been
successfully applied in animals and proved to be effective in enhancing the insulin
sensitivity  and  energy  homeostasis,  alleviating  the  obesity-associated
inflammatory injuries,  as  well  as  preventing the  formation and development  of
various cancers. However, the direct translation of animal studies to human turns
out  to  be  a  challenge.  Unlike  other  metabolic  hormones  (such  as  insulin),
adiponectin  is  a  highly  abundant  plasma  protein  in  humans.  Long-term
replacement  of  bioactive  adiponectin  is  not  cost-effective  and  feasible  at  this
stage. Different oligomeric forms of adiponectin and the quality of the preparation
significantly affect  experimental  outcome and have impeded the clinical  use of
adiponectin.  For  the  same  reason,  our  current  understanding  of  the  mode  of
adiponectin function at the molecular level has been compromised. Considering
the highly dynamic and complexed structural-signaling mechanisms, approaches
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to up-regulate the endogenous adiponectin levels are more appealing for cancer
prevention and treatment. Alternatively, the identification of the true functional
moieties of adiponectin will greatly enhance the process of future drug discovery
and  development,  especially  in  therapeutic  applications  for  obesity-related
medical  complications.
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